The transaction, which officially closed on July 23, 2026, was facilitated by FT Global Capital, Inc. acting as the exclusive placement agent. The shares were issued under a shelf registration statement originally filed with the U.S. Securities and Exchange Commission in early 2024.
China Pharma Holdings Secures $5 Million in Direct Share Offering
Haikou-based China Pharma Holdings has finalized a registered direct offering of 2.5 million common shares, successfully raising $5 million in gross proceeds. The company, listed on the NYSE American, executed the sale at a price of $2.00 per share to bolster its general corporate reserves and working capital.
China Pharma Holdings operates as a specialty pharmaceutical firm focused on high-mortality conditions such as cardiovascular and infectious diseases. With its manufacturing hub centered in Hainan Province through its subsidiary, Hainan Helpson Medical & Biotechnology, the company maintains eight GMP-certified production lines intended to serve its broad distribution network across China.
Comments (0)
No comments yet. Be the first!